NEW YORK (GenomeWeb News) — Spectrumedix, a maker of high-throughput capillary-electrophoresis tools, closed its doors last month, according to Transgenomic, a Spectrumedix distributor.
To make up for the resulting supply problems created by the dissolution, which occurred March 9, Transgenomic said it has purchased “certain assets” from the company’s court-appointed receiver along with a license to a gel patent it needs to make consumables for the Spectrumedix systems.
Transgenomic will continue to offer service and support to Spectrumedix customers in the US and elsewhere. The company said Spectrumedix-made tools are used in comparative genome scanning, SNP genotyping, heterozygote identification, fragment sizing, PCR quality testing, and custom assay development.
Transgenomic CEO Craig Tuttle said the company has been “concerned” about the supply of consumables and spare parts to its customers in Europe, and said this series of moves “clarifies the situation” for former Spectrumedix customers as well.
Financial terms of the deal were not released.